Cytos Biotechnology Ltd to Host Investor and Analyst R&D Day in New York City
SCHLIEREN, ZURICH, Switzerland, October 17, 2013 /PRNewswire/ --
Cytos Biotechnology Ltd (SIX:CYTN) will host an Investor and Analyst R&D Day for institutional investors and research analysts on
Wednesday, October 23, 2013 from 8:00 a.m. to 10:00 a.m. ET in New York City
Christian Itin, Chairman and CEO as well as senior executives of Cytos will present on Cytos' lead program CYT003, which is in clinical development for the treatment of allergic asthma.
Expert medical and scientific leaders in the field of asthma clinical research will be featured speakers at the meeting:
- Thomas B. Casale, MD, Professor of Medicine, University of South Florida School of Medicine, Tampa, Florida
- Kai-Michael Beeh, MD, Medical Director of insaf Respiratory Research Institute, Wiesbaden, Germany
A live webcast of the Investor and Analyst R&D Day can be accessed by visiting the investor relations section of Cytos' website at: http://www.videonewswire.com/event.asp?id=96505
Participant Dial-in numbers for conference call:
Participant Dial In (Toll Free): + 1-877-870-4263
Participant International Dial In: + 1-412-317-0790
About CytosBiotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma.
CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, including that CYT003 may not demonstrate safety or efficacy in clinical trials, that there may be delays in development or that CYT003 may not receive marketing approval, and that the Company relies on outside financing to meet capital requirements, which may not be available under acceptable terms or at all. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
For further information, please contact:
Cytos Biotechnology Ltd
Chief Financial Officer
US investor Enquiries and details to attend the NYC meeting:
Susan A. Noonan
SOURCE Cytos Biotechnology Ltd